Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AVIGEN(avgn) -- Ignore unavailable to you. Want to Upgrade?

To: JMarcus who wrote (154)	11/1/1999 9:01:00 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 228

biz.yahoo.com Monday November 1, 8:38 am Eastern Time Company Press Release SOURCE: Avigen Avigen Reports in Vivo Delivery and Long-Term Expression of Factor VIII Gene For Hemophilia A ALAMEDA, Calif., Nov. 1 /PRNewswire/ -- In a gene therapy study targeting the potential treatment of hemophilia A, Avigen (Nasdaq: AVGN - news) scientists today announced that a single administration of an adeno-associated vector (AAV) carrying the gene for factor VIII produced physiological levels of biologically active clotting factor in the plasma of animals. Significant levels of factor VIII have persisted in these animals for nearly two years. (snip)